

H g K g E cha ge, a d C ea g L ed a d The S c E cha ge f H g K g L ed a e e, b yf he c e, f h, a ce e, a e e e a a, ac, acy c e e e, a d e e, y d, c a a y ab y ha, e e f a y, h, e e a, g f e a ce, he h e a y a f h e c e, f h, a ce e.

# FOSUN PHARMA

## 复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

(a c ed c a y c a ed he Pe e, Re, b c f Ch a h ed ab y)

(Stock Code: 02196)

### 2019 THIRD QUARTERLY REPORT

This report is prepared in accordance with the requirements of the Securities and Futures Ordinance (Cap. 571) and the Listing Rules of the Stock Exchange of Hong Kong Limited. This report is prepared in accordance with the requirements of the Securities and Futures Ordinance (Cap. 571) and the Listing Rules of the Stock Exchange of Hong Kong Limited.

This report is prepared in accordance with the requirements of the Securities and Futures Ordinance (Cap. 571) and the Listing Rules of the Stock Exchange of Hong Kong Limited. This report is prepared in accordance with the requirements of the Securities and Futures Ordinance (Cap. 571) and the Listing Rules of the Stock Exchange of Hong Kong Limited.

B  
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*  
Chen Qiyu  
Chairman

This report is prepared in accordance with the requirements of the Securities and Futures Ordinance (Cap. 571) and the Listing Rules of the Stock Exchange of Hong Kong Limited. 29 October 2019

A a h e d a e f h, a ce e, h e e a, e d e c, f h e C a y a e M. Che Q, M. Ya Fa g a d M. W, Yfa g; h e e a, e d e c, f h e C a y a e M. X, X a a g, M. Wa g Ca, M, M, Ha g a d M. La g Ja fe g; a d h e d e e d e e a, e d e c, f h e C a y a e M. Ja g X a, D. W g T Ya, Ke, M, L L g a d M. Ta g G, a g.

\* f de fca y, e, y

# 1. IMPORTANT NOTICE

1.1 The Board (the "Board") (the "Supervisory Committee") C. 2019 The Q. R. G. S. S. b.

1.2 A C. B. 2019 The Q. R. G.

1.3 C. Q. D. A. (A. O.) C. F. O. 2019 The Q. R. G.

1.4 The 2019 The Q. R. G. s. b.

## 2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

### 2.1 Major financial information

Unit: million RMB

	30 September 2019	31 December 2018	Ratio of change (%)
Total assets	78,569,297,725.65	70,551,361,387.48	11.36
Net assets attributable to shareholders	30,633,746,877.27	27,977,736,427.49	9.49
	Jan – Sept 2019	Jan – Sept 2018	Period-on-period change (%)
Net income	2,328,355,784.17	2,087,826,458.74	11.52
	Jan – Sept 2019	Jan – Sept 2018	Period-on-period change (%)
Operating Revenue	21,227,618,679.11	18,142,384,871.95	17.01
Net income attributable to shareholders	2,063,704,147.99	2,094,152,353.81	-1.45
Net income attributable to shareholders of the parent	1,722,388,028.34	1,591,668,096.39	8.21
Profit margin (%)	7.21	8.00	Decrease 0.79 percentage points
Basic earnings per share (RMB)	0.81	0.83	-2.41
Diluted earnings per share (RMB)	0.81	0.83	-2.41

Note: In September 2019, the total assets attributable to shareholders (including minority interests), net assets attributable to shareholders, net income attributable to shareholders, earnings per share and diluted earnings per share of the Group were RMB554.7841 million, RMB163.7726 million, RMB41.88 million, RMB1.722388 and RMB1.307199, respectively, compared with RMB554.7841 million, RMB163.7726 million, RMB41.88 million, RMB1.722388 and RMB1.307199, respectively, in September 2018.

During the reporting period, the total assets attributable to shareholders (including minority interests), net assets attributable to shareholders, net income attributable to shareholders, earnings per share and diluted earnings per share of the Group were RMB-7.1998 million, RMB149.8699 million, RMB341.3161 million, RMB-0.0072 million and RMB161.1681 million, respectively, compared with RMB-7.1998 million, RMB149.8699 million, RMB341.3161 million, RMB-0.0072 million and RMB161.1681 million, respectively, in the corresponding period of 2018.

Basic earnings per share of the Group was RMB0.81 in September 2019, compared with RMB0.83 in September 2018, a decrease of 1.45%.

During the reporting period, the operating revenue of the Group was RMB2,253.454 million, compared with RMB386.4802 million in the corresponding period of 2018, an increase of 20.70%. The net income attributable to shareholders of the parent was RMB2,328.3558 million, compared with RMB2,087.8265 million in the corresponding period of 2018, an increase of 11.52%.

E

Unit: RMB

Items	Jul – Sept 2019	Jan – Sept 2019
G	6,698,974.15	54,877,229.54
G	64,610,828.53	123,804,343.06
P	-95,402,673.43	231,996,093.58
N	48,756,541.22	27,391,712.25
I	-15,445,568.08	-33,058,160.48
E	-16,417,943.49	-63,695,098.30
T	-7,199,841.10	341,316,119.65

2.2 The number of shares held by the Top 10 shareholders at the end of the period is 127,272. The shareholding status of the Top 10 shareholders is as follows:

The shareholding status of the Top 10 shareholders		Name of shareholders		Shareholding at the end of the period	


The shareholding status of the Top 10 unrestricted shareholders			
Name of the shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type	Number
SHANGHAI FOSUN HIGH TECHNOLOGY (GROUP) COMPANY LIMITED*	938,095,290	RMB ordinary shares	938,095,290
HKSCC NOMINEES LIMITED (Note 1)	551,255,448	Ordinary shares	551,255,448
CHINA SECURITIES FINANCE CORPORATION LIMITED*	38,736,157	RMB ordinary shares	38,736,157
HONG KONG SECURITIES CLEARING COMPANY LIMITED (Note 2)	36,199,707	RMB ordinary shares	36,199,707
NATIONAL SOCIAL SECURITY FUND 113 PORTFOLIO*	28,066,210	RMB ordinary shares	28,066,210
BASIC PENSION INSURANCE FUND 802 PORTFOLIO*	25,824,892	RMB ordinary shares	25,824,892
CENTRAL HUIJIN ASSET MANAGEMENT LTD.*	24,067,700	RMB ordinary shares	24,067,700
NATIONAL SOCIAL SECURITY FUND 110 PORTFOLIO*	15,358,518	RMB ordinary shares	15,358,518
ABU DHABI INVESTMENT AUTHORITY	13,790,532	RMB ordinary shares	13,790,532
CHINA CONSTRUCTION BANK CORPORATION—CHINA-EUROPEAL ENERGY SECURITIES INVESTMENT FUND*	10,198,273	RMB ordinary shares	10,198,273
Discontinued operations		Discontinued operations	
Discontinued operations		Discontinued operations	

Note 1: HKSCC NOMINEES LIMITED, a wholly-owned subsidiary of the Hong Kong Securities Clearing Company Limited, holds 551,255,448 ordinary shares of the Company, representing 34.993,500% of the total number of shares of the Company. The shares are held in the name of the Hong Kong Securities Clearing Company Limited as nominee for the Fosun High Tech (Group) Company Limited ("Fosun High Tech"). The shares are held in the name of the Hong Kong Securities Clearing Company Limited as nominee for the Fosun High Tech (Group) Company Limited ("Fosun High Tech").

Note 2: HONG KONG SECURITIES CLEARING COMPANY LIMITED holds 36,199,707 ordinary shares of the Company, representing 2.37% of the total number of shares of the Company. The shares are held in the name of the Hong Kong Securities Clearing Company Limited as nominee for the Hong Kong Securities Clearing Company Limited.

2.3 The Company's shareholding structure is as follows: The top 10 shareholders of the Company are as follows: Fosun High Tech (Group) Company Limited, HKSCC Nominees Limited, China Securities Finance Corporation Limited, Hong Kong Securities Clearing Company Limited, National Social Security Fund 113 Portfolio, Basic Pension Insurance Fund 802 Portfolio, Central Huijin Asset Management Ltd., National Social Security Fund 110 Portfolio, Abu Dhabi Investment Authority, and China Construction Bank Corporation—China-Europeal Energy Securities Investment Fund.

Note: b









As of December 31, 2019, Fosun Pharmaceutical (Group) Co., Ltd. held 2,560,000 H Shares of Shanghai Henlius Biotech, Inc. (Shanghai Henlius) at a cost of RMB53.54 million, representing 0.10% of Shanghai Henlius Biotech, Inc.'s total shares as of December 31, 2019.

3. On November 27, 2018, Fosun Pharmaceutical (Group) Co., Ltd. completed the acquisition of 100% equity interest in Shanghai Henlius Biotech, Inc. ("Shanghai Henlius"), a company incorporated in the People's Republic of China, through its wholly owned subsidiary, Fosun Pharmaceutical (Group) Co., Ltd. (Shanghai Henlius) ("Shanghai Henlius"). Shanghai Henlius Biotech, Inc. is listed on the Hong Kong Stock Exchange ("Hong Kong Stock Exchange").

On September 25, 2019, Fosun Pharmaceutical (Group) Co., Ltd. completed the acquisition of 100% equity interest in Shanghai Henlius Biotech, Inc. through its wholly owned subsidiary, Fosun Pharmaceutical (Group) Co., Ltd. (Shanghai Henlius) ("Shanghai Henlius"). Shanghai Henlius Biotech, Inc. is listed on the Hong Kong Stock Exchange ("Hong Kong Stock Exchange"). Shanghai Henlius Biotech, Inc. had 64,695,400 H Shares outstanding as of September 30, 2019, with a closing price of HK\$49.60. The total consideration for the acquisition was HK\$3,208.89 million (equivalent to RMB2,100.00 million), of which RMB1,000.00 million was paid in cash. As of September 30, 2019, the acquisition cost represented 53.76% of the total consideration.

On October 17, 2019, Fosun Pharmaceutical (Group) Co., Ltd. completed the acquisition of 100% equity interest in Shanghai Henlius Biotech, Inc. through its wholly owned subsidiary, Fosun Pharmaceutical (Group) Co., Ltd. (Shanghai Henlius) ("Shanghai Henlius"). Shanghai Henlius Biotech, Inc. is listed on the Hong Kong Stock Exchange ("Hong Kong Stock Exchange"). Shanghai Henlius Biotech, Inc. had 4,366,400 H Shares outstanding as of October 17, 2019, with a closing price of HK\$49.60. The total consideration for the acquisition was HK\$210.49 million (equivalent to RMB133.00 million), of which RMB60.00 million was paid in cash. As of October 17, 2019, the acquisition cost represented 53.33% of the total consideration.

### 3.3 Fosun Pharmaceutical (Group) Co., Ltd. RMB Denominated Shares

N/A

### 3.4 Fosun Pharmaceutical (Group) Co., Ltd. H Shares

N/A

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Legal Representative: Chen Qiyu

29 October 2019

## 4. APPENDICES

### 4.1 Financial statements

#### Consolidated balance sheet

30 September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Unit: RMB Tenthousand Yuan

Items	30 September 2019	31 December 2018
<b>Current assets:</b>		
Cash and bank balances	10,307,237,302.85	8,546,521,777.04
Financial assets at fair value through profit or loss	1,344,673,568.10	616,123,764.39
Derivatives	258,620,513.78	712,510,581.95
Trade receivables	4,463,034,533.86	3,623,640,740.82
Receivables from related parties	471,597,865.70	—
Prepaid expenses	596,927,301.93	472,144,580.30
Other receivables	577,591,869.92	447,434,579.55
Interest receivable	9,995,755.01	11,660,016.68
Dividends receivable	36,917,475.21	19,731,451.25
Inventory	3,858,842,830.18	3,287,392,199.46
Non-current financial assets at fair value through profit or loss	—	—
Assets held for sale	1,162,820,637.56	—
Other financial assets at fair value through profit or loss	368,970,686.90	295,958,970.62
Trustee assets	23,410,317,110.78	18,001,727,194.13
<b>Non-current assets:</b>		
Derivative financial assets	117,956,750.00	67,562,000.00
Long-term financial assets at fair value through profit or loss	21,198,447,942.66	21,427,527,810.80
Other financial assets at fair value through profit or loss	100,986,503.54	126,313,106.69
Other financial assets at fair value through other comprehensive income	2,100,733,208.89	2,505,806,955.75
Fixed assets	7,291,387,236.53	7,083,251,505.14
Construction in progress	2,942,095,697.03	2,039,800,319.91
Right-of-use assets	433,996,758.51	—
Intangible assets	7,873,710,459.21	7,151,343,109.87
Development expenditures	2,676,735,574.42	2,040,773,501.88
Goodwill	9,187,137,617.57	8,853,913,413.52
Long-term equity investments	114,180,385.70	95,198,631.30
Deferred tax assets	242,021,035.79	173,134,814.17
Other non-current assets	879,591,445.02	985,009,024.32
Trustee non-current assets	55,158,980,614.87	52,549,634,193.35
Total	78,569,297,725.65	70,551,361,387.48

**Consolidated balance sheet (Continued)**

30 September 2019

Items	30 September 2019	31 December 2018
<b>Current liabilities:</b>		
Short-term borrowings	7,440,018,220.78	5,607,192,955.63
Bills payable	266,942,486.20	149,003,072.96
Trade payables	2,233,670,981.77	2,184,280,272.14
Prepaid expenses	562,709,265.76	578,701,499.77
Trade receivables	451,969,450.66	478,905,270.26
Other payables	4,178,903,272.34	3,237,217,890.12
Interest payable	220,768,148.00	187,344,429.18
Dividends payable	139,956,011.68	125,420,505.60
Contract liabilities	388,047,456.85	530,896,724.79
Non-current liabilities	2,206,056,772.37	4,929,603,365.34
Other payables	1,599,149,293.47	227,445,337.32
Trade payables	19,327,467,200.20	17,923,246,388.33
<b>Non-current liabilities:</b>		
Long-term borrowings	8,816,140,333.28	8,630,661,547.43
Bills payable	5,781,204,728.90	4,039,456,986.21
Long-term payables	307,212,833.42	—
Long-term payables	252,679,111.96	416,889,805.19
Deferred income	358,341,043.66	363,489,177.57
Deferred income	2,895,818,060.31	2,908,359,008.27
Other long-term liabilities	2,878,227,018.69	2,676,545,098.82
Trade payables	21,289,623,130.22	19,035,401,623.49
Trade payables	40,617,090,330.42	36,958,648,011.82
<b>Equity:</b>		
Parent's equity (attributable to the parent)	2,562,898,545.00	2,563,060,895.00
Minority interest	11,918,086,638.94	10,544,648,359.54
Less: Treasury shares	—	1,711,169.00
Other comprehensive income	-238,833,703.62	-274,779,732.99
Surplus reserves	2,373,685,050.45	2,374,999,312.51
Retained earnings	14,017,910,346.50	12,771,518,762.43
Total (attributable to the parent)	30,633,746,877.27	27,977,736,427.49
Non-current liabilities	7,318,460,517.96	5,614,976,948.17
Trade payables (attributable to the parent)	37,952,207,395.23	33,592,713,375.66
Trade payables (attributable to the parent)	78,569,297,725.65	70,551,361,387.48

Legal Representative:  
**Chen Qiyu**

Chief Financial Officer:  
**Guan Xiaohui**

Deputy Accounting Director:  
**Chen Zhanyu**

## Balance Sheet of the Parent Company

30 September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Currency: RMB Tenthousand Yuan

Items	30 September 2019	31 December 2018
<b>Current assets:</b>		
Cash and cash equivalents	1,106,498,344.52	850,102,168.54
Financial assets		
Prepaid expenses		
Other receivables	6,407,634,690.21	6,914,735,852.92
Inventory: Inventory	299,410,098.84	230,691,574.83
Due from subsidiaries	354,609,680.05	307,409,680.05
Intangible assets	—	—
Non-current financial assets	2,536,000,000.00	1,625,000,000.00
Other non-current assets	239,000,000.00	158,570,000.00
Total current assets	10,289,133,034.73	9,548,408,021.46
<b>Non-current assets:</b>		
Due to subsidiaries	6,011,804,080.60	5,465,151,645.71
Long-term investments	23,961,991,164.92	22,999,277,541.00
Other non-current assets	37,689,534.30	37,626,487.24
Other non-current liabilities	147,179,403.98	184,188,803.45
Financial liabilities	6,217,807.54	7,158,298.77
Current liabilities	2,305,418.41	2,305,418.41
Intangible liabilities	1,398,139.68	1,840,272.04
Deferred tax assets		
Goodwill		
Long-term non-current liabilities		
Deferred tax liabilities		
Total non-current assets	30,168,585,549.43	28,697,548,466.62
Total assets	40,457,718,584.16	38,245,956,488.08

**Balance Sheet of the Parent Company (Continued)**

30 September 2019

Items	30 September 2019	31 December 2018
<b>Current liabilities:</b>		
Short-term borrowings	3,825,000,000.00	2,959,000,000.00
Bank deposits		
Receivables		
Contract liabilities		
Financial liabilities	94,480,035.63	124,637,901.93
Trade payables	25,239,506.72	43,694,651.68
Other payables	1,715,449,403.09	1,357,247,173.94
Interest liabilities	213,542,735.45	172,658,261.16
Derivative liabilities	229,468.00	229,468.00
Non-current liabilities	1,267,088,795.71	3,769,010,861.94
Other non-current liabilities	1,304,675,980.01	5,313,103.87
Total current liabilities	8,231,933,721.16	8,258,903,693.36
<b>Non-current liabilities:</b>		
Long-term borrowings	346,740,000.00	66,740,000.00
Bank deposits	5,781,204,728.90	4,039,456,986.21
Long-term contract liabilities		
Derivative liabilities	325,000.00	550,000.00
Derivative liabilities	1,151,018,873.79	1,151,018,873.79
Other non-current liabilities		
Total non-current liabilities	7,279,288,602.69	5,257,765,860.00
Total liabilities	15,511,222,323.85	13,516,669,553.36
<b>Equity:</b>		
Parent's equity (attributable to the parent)	2,562,898,545.00	2,563,060,895.00
Minority interest	14,247,927,508.28	14,231,054,756.04
Less: Treasury shares	—	1,711,169.00
Other comprehensive income	-327,370,661.53	-279,100,142.24
Surplus reserves	1,247,565,522.50	1,247,565,522.50
Reserves for contingencies	7,215,475,346.06	6,968,417,072.42
Total equity (attributable to shareholders)	24,946,496,260.31	24,729,286,934.72
Total liabilities and equity (attributable to shareholders)	40,457,718,584.16	38,245,956,488.08

Legal Representative:  
**Chen Qiyu**

Chief Financial Officer:  
**Guan Xiaohui**

Director of Accounting Department:  
**Chen Zhanyu**



**Consolidated Income Statement (Continued)**

January - September 2019

Items	July - Sept 2019	July - Sept 2018	Jan - Sept 2019	Jan - Sept 2018
I. Operating Income	-9,016,755.16	-122,010,941.32	34,958,479.93	-532,197,468.31
Operating Income before Income Tax	7,142,372.12	-173,180,224.69	35,946,029.37	-571,964,925.72
( ) Operating Income after Income Tax	144,152.81	3,756,815.51	-26,694,169.11	-101,521,914.06
1. Income from operations	—	—	—	—
2. Income from other operations	—	—	—	—
3. Income from other operations	144,152.81	3,756,815.51	-26,694,169.11	-101,521,914.06
4. Income from other operations	—	—	—	—
( ) Income from operations	6,998,219.31	-176,937,040.20	62,640,198.48	-470,443,011.66
1. Income from operations	-27,514,726.87	22,492,035.64	-57,540,529.80	29,149,580.97
2. Income from operations	34,512,946.18	-199,429,075.84	120,180,728.28	-499,592,592.63
Income from operations before Income Tax	-16,159,127.28	51,169,283.37	-987,549.44	39,767,457.41
II. Total Income	626,951,292.40	479,073,767.81	2,490,555,469.23	1,806,839,053.77
Total Income before Income Tax	554,726,673.16	360,501,362.79	2,099,650,177.36	1,522,187,428.09
Total Income after Income Tax	72,224,619.24	118,572,405.02	390,905,291.87	284,651,625.68
III. Earnings				
( ) Basic Earnings	0.22	0.20	0.81	0.83
( ) Diluted Earnings	0.22	0.20	0.81	0.83

Legal Representative:  
**Chen Qiyu**

Chief Financial Officer:  
**Guan Xiaohui**

Deputy Accounting Director:  
**Chen Zhanyu**



## Income Statement of the Parent Company

January – September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Currency: RMB Tenthousand Yuan

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. Operating Income	3,815,974.06	—	5,685,313.69	9,433.96
Less: Operating Expenses	—	—	—	—
Transportation Expenses	1,138,885.77	—	2,411,699.94	43,754.06
Sales and Distribution Expenses	—	—	—	—
General and Administrative Expenses	65,458,328.69	72,278,881.00	136,505,943.90	151,588,516.01
Research Expenses	1,400,270.20	—	2,952,245.60	—
Financial Expenses	24,847,472.18	29,794,031.27	105,319,187.87	78,043,266.55
Interest Income	143,806,935.92	120,916,769.27	411,681,720.73	331,017,960.01
Interest Expense	110,395,009.96	101,566,901.47	300,636,180.35	266,631,390.40
Assets Impairment Losses	—	—	—	—
Credit Impairment Losses	—	—	—	—
Plus: Other Income	110,486.49	75,000.00	300,849.09	225,000.00
Interest Income (“—” for loss)	438,727,482.59	409,853,353.52	1,342,948,533.13	1,328,284,941.99
Interest Income from Associates	430,736,612.25	389,199,792.25	1,250,403,969.29	1,156,577,651.49
Gain from Disposal of Intangible Assets (“—” for loss)	—	—	—	—
Gain from Disposal of Long-Term Equity Investments (“—” for loss)	-14,794,694.59	66,221,631.43	-36,067,868.78	90,531,856.25
Gain from Disposal of Subsidiaries (“—” for loss)	7,349.80	-886.58	7,349.80	-886.58
II. Operating Income (“—” for loss)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Plus: Non-Operating Income	—	—	—	—
Less: Non-Operating Expenses	—	—	—	—
III. Total Income (“—” for loss)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Less: Income Tax	—	—	—	—
IV. Net Income (“—” for loss)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
() Net Income from Continuing Operations (“—” for loss)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
() Net Income from Discontinued Operations (“—” for loss)	—	—	—	—







|





Items	31 December 2018	1 January 2019	Adjustment
<b>Non-current liabilities:</b>			
Long-term debt	8,630,661,547.43	8,630,661,547.43	
Bonds payable	4,039,456,986.21	4,039,456,986.21	
Interest payable	—	—	
Provision for doubtful accounts	—	—	
Losses on sale of investments	—	325,992,167.00	-325,992,167.00
Long-term debt, net	416,889,805.19	398,095,841.52	18,793,963.67
Deferred income taxes	363,489,177.57	363,489,177.57	
Deferred compensation	2,908,359,008.27	2,908,359,008.27	
Other non-current liabilities	2,676,545,098.82	2,676,545,098.82	
Total non-current liabilities	19,035,401,623.49	19,342,599,826.82	-307,198,203.33
Total liabilities	36,958,648,011.82	37,348,299,890.45	-389,651,878.63
<b>Equity (or shareholders' interests):</b>			
Preferred stock	2,563,060,895.00	2,563,060,895.00	
Common stock	10,544,648,359.54	10,544,648,359.54	
Less: treasury stock	1,711,169.00	1,711,169.00	
Other equity	-274,779,732.99	-274,779,732.99	
Share-based compensation	2,374,999,312.51	2,374,999,312.51	
Retained earnings	12,771,518,762.43	12,771,518,762.43	
Total equity	27,977,736,427.49	27,977,736,427.49	
Net assets	5,614,976,948.17	5,614,976,948.17	
Total Equity (or shareholders' interests)	33,592,713,375.66	33,592,713,375.66	
Total liabilities and equity	70,551,361,387.48	70,941,013,266.11	-389,651,878.63

Equity (or shareholders' interests):

For 1 January 2019, the Government of New Jersey State Treasurer's Office (MOF).

Interest on long-term debt, net of non-current liabilities, State Treasurer's Office (MOF) for 2019. The Government of New Jersey State Treasurer's Office (MOF) is a public entity.



## Balance Sheet of the Parent Company

Currency: RMB

Items	31 December 2018	1 January 2019	Adjustment
<b>Current assets:</b>			
Cash and bank balances	850,102,168.54	850,102,168.54	
Accounts receivable	6,914,735,852.92	6,914,735,852.92	
Inventory	230,691,574.83	230,691,574.83	
Due from subsidiaries	307,409,680.05	307,409,680.05	
Net investment in subsidiaries	1,625,000,000.00	1,625,000,000.00	
Other receivables	158,570,000.00	158,570,000.00	
Term deposits	9,548,408,021.46	9,548,408,021.46	
<b>Non-current assets:</b>			
Due from subsidiaries	5,465,151,645.71	5,465,151,645.71	
Long-term investments	22,999,277,541.00	22,999,277,541.00	
Other receivables	37,626,487.24	37,626,487.24	
Other investment in subsidiaries	184,188,803.45	184,188,803.45	
Financial assets	7,158,298.77	7,158,298.77	
Costs of investments in subsidiaries	2,305,418.41	2,305,418.41	
Intangible assets	1,840,272.04	1,840,272.04	
Term deposits	28,697,548,466.62	28,697,548,466.62	
Term deposits	38,245,956,488.08	38,245,956,488.08	
<b>Current liabilities:</b>			
Accounts payable	2,959,000,000.00	2,959,000,000.00	
Accounts payable	124,637,901.93	124,637,901.93	
Accounts payable	43,694,651.68	43,694,651.68	
Accounts payable	1,357,247,173.94	1,357,247,173.94	
Inventory	172,658,261.16	172,658,261.16	
Due to subsidiaries	229,468.00	229,468.00	
Net investment in subsidiaries	3,769,010,861.94	3,769,010,861.94	
Accounts payable	5,313,103.87	5,313,103.87	
Term deposits	8,258,903,693.36	8,258,903,693.36	

Items	31 December 2018	1 January 2019	Adjustment
<b>Non-current liabilities:</b>			
Long-term debt	66,740,000.00	66,740,000.00	
Bonds payable	4,039,456,986.21	4,039,456,986.21	
Interest payable	—	—	
Provision for doubtful accounts	—	—	
Deferred income taxes	550,000.00	550,000.00	
Deferred tax liabilities	1,151,018,873.79	1,151,018,873.79	
Trade payables	5,257,765,860.00	5,257,765,860.00	
Trade receivables	13,516,669,553.36	13,516,669,553.36	
Equity (including minority interests):			
Preferred stock	2,563,060,895.00	2,563,060,895.00	
Common stock	14,231,054,756.04	14,231,054,756.04	
Less: treasury stock	1,711,169.00	1,711,169.00	
Other comprehensive income	-279,100,142.24	-279,100,142.24	
Share-based payments	1,247,565,522.50	1,247,565,522.50	
Retained earnings	6,968,417,072.42	6,968,417,072.42	
Total (including minority interests)	24,729,286,934.72	24,729,286,934.72	
Total liabilities and equity (including minority interests)	38,245,956,488.08	38,245,956,488.08	

### 4.3 Explanation on retrospective adjustments to previous comparative data for the initial implementation of New Financial Instruments Standards and New Lease Standards

For 1 January 2019, the Group has adopted the New Lease Standards and New Financial Instruments Standards issued by the MOF.

In accordance with the requirements of the New Lease Standards, the Group has retrospectively adjusted the comparative data for 2019. The Group has also adopted the New Financial Instruments Standards issued by the MOF.

### 4.4 Audited report

N. ... b